In recent years, we’ve witnessed several high-profile pharmaceutical launches that have set new benchmarks for success. Yet, for every standout case, there are numerous products that have struggled to achieve their revenue potential, leading to unfortunate consequences – most notably, patients being unable to access the medicines they need.
A poor launch not only hampers financial success but can also derail an effective lifecycle indication programme, further compounding the missed opportunities. The essential link between successful pharmaceutical launches and the establishment of multi-indication medicines lies in a robust early commercialisation strategy. To navigate this landscape effectively, we focus on four critical areas that can set the course for a differentiated and competitive medicine.
Future scope
Every pharmaceutical company invests in competitive intelligence, yet it’s crucial to extend this effort beyond simply tracking competitors’ mechanisms of action (MOAs) in development and their expected market entry dates. Effective teams delve deep into anticipated market conditions, often looking 10-12 years into the future. This forward-thinking perspective ensures that assets are optimally positioned not just at launch but throughout their lifecycle. A successful strategy involves clarity in three key areas:
- Unmet need: Identifying what the most pressing unmet needs will be at launch and beyond, rather than merely focusing on the current landscape.
- Payer environment: Analysing how decision making will evolve to comprehend what profiles will be necessary for optimal pricing and access, especially in markets increasingly populated by generics, biosimilars, and competing assets with head-to-head data.
- Regulatory requirements: Anticipating evolving regulatory expectations in therapeutic areas and ensuring these are addressed early, ideally within the phase 2 programme.
Tailoring the development programme for the future
With a clear vision set, it is imperative that the development programme is meticulously tailored to meet future needs. Cross-functional collaboration becomes essential to ensure the phase 2 programme tests the medicine against endpoints that will support optimal differentiation, pricing, and access. The outcome of phase 2 testing should lead seamlessly into phase 3, reinforcing the importance of objective ‘go/no-go’ criteria. This approach mitigates emotional biases in governance decisions, empowering organisations to channel investments into the most promising assets.
Effective early lifecycle management planning
A recurring issue in the industry is the late or absent planning of follow-on indication strategies. Successful medicines develop their lifecycle management plans as rigorously and early as the priority indication. During the phase 2 process, a comprehensive assessment and prioritisation of potential indications should occur.
This evaluation must weigh the scientific rationale and unmet needs alongside commercial attractiveness while considering synergies with the lead indication. Timing, access impacts, pricing strategies, and potential risks should also be assessed. It is no coincidence that the best-performing medicines have robust lifecycle management programmes operating in parallel with their lead indications. The emphasis is shifted from merely the first indication launch to maximising the asset’s total value.
Deploying your best people early
The backbone of the most successful and impactful medicines in the industry lies in getting early commercialisation right. This leads to our final challenge: ensuring that the right people are engaged as early as possible. The instinct often is to place the brightest strategic minds in charge of launches. However, it is our view that these key talents should be deployed earlier. Their focus should be on setting the optimal course, working collaboratively with development teams, nurturing relationships with global opinion leaders, and crafting a compelling future proposition. Such investment early in the process not only increases the likelihood of a successful launch but also maximises patient benefit across multiple indications.
Unlocking potential
Across so many of our early commercialisation projects with our pharmaceutical clients, we have seen first-hand that a proactive and comprehensive approach significantly enhances the chances of success.
It is paramount to focus on future market dynamics, tailoring development programmes, meticulously planning lifecycle management, and deploying top talent early, to unlock full potential. As we partner with pharmaceutical organisations to guide them through these critical phases, it is hugely motivational to know that we are ensuring that their products not only launch successfully but also thrive in the marketplace and ultimately deliver vital medicines to patients in need.
Contact us
